← Back to Search

Antioxidant

Lipoic acid treatment for Atherosclerosis

Phase 2 & 3

Waitlist Available

Led By Gerd Bobe, PhD

Research Sponsored by Oregon State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12,20 & 32 weeks

Awards & highlights

Study Summary

This trial will test if a supplement can reduce risk factors for heart disease in people with high levels of inflammation.

Eligible Conditions

Atherosclerosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12,20 & 32 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12,20 & 32 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12,20 & 32 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

hs-CRP

Secondary outcome measures

8-lso-PGF2a

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Lipoic acid treatmentActive Control1 Intervention

Participants take lipoic acid with a washout period before or after placebo.

Group II: Placebo treatmentPlacebo Group1 Intervention

Participants take placebo with a washout period before or after lipoic acid treatment

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityOTHER

973 Previous Clinical Trials

7,385,762 Total Patients Enrolled

1 Trials studying Atherosclerosis

100 Patients Enrolled for Atherosclerosis

Oregon State UniversityLead Sponsor

49 Previous Clinical Trials

8,331 Total Patients Enrolled

1 Trials studying Atherosclerosis

100 Patients Enrolled for Atherosclerosis

National Center for Complementary and Integrative Health (NCCIH)NIH

832 Previous Clinical Trials

668,883 Total Patients Enrolled

5 Trials studying Atherosclerosis

620 Patients Enrolled for Atherosclerosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To whom is this clinical trial available?

"The ideal candidate for this study should have atherogenesis, be between the ages of 50 and 70, and out of a pool of 50 potential participants."

Answered by AI

Does this research include individuals above the age of 40 in its sample population?

"According to the age guidelines set out in this study's inclusion criteria, the oldest somebody can be and still participate is 70, while the youngest is 50."

Answered by AI

Are patients being actively sought for participation in this research?

"The study in question is not looking for new patients at the moment, however this could change in the future. According to the website clinicaltrials.gov, which last updated information about this trial on April 19th 2022, the 241 other trials might be of interest."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease

Gerd Bobe 2011. "The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00764270.